Affimed N.V.
AFMD
Price:
$1.19
Market Cap:
$17.43M
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid ...[Read more]
Industry
Biotechnology
IPO Date
2014-09-12
Stock Exchange
NASDAQ
Ticker
AFMD
PE Ratio
[-0.25]
ROE
[-193.85%]
Current Ratio
[1.93]
Dividend Yield
[0%]
Enterprise Value
[22.91M]
Dividend History
The ROE as of December 2024 (TTM) for Affimed N.V. (AFMD) is -193.85%
According to Affimed N.V.’s latest financial reports and current stock price. The company's current ROE is -193.85%. This represents a change of 246.22% compared to the average of -55.99% of the last 4 quarters.
Affimed N.V. (AFMD) Historical ROE (quarterly & annually)
How has AFMD ROE performed in the past?
The mean historical ROE of Affimed N.V. over the last ten years is -68.13%. The current -193.85% ROE has changed 184.55% with respect to the historical average. Over the past ten years (40 quarters), AFMD's ROE was at its highest in in the December 2018 quarter at 21.83%. The ROE was at its lowest in in the September 2024 quarter at -88.04%.
Average
-68.13%
Median
-56.85%
Minimum
-183.26%
Maximum
-0.81%
Affimed N.V. (AFMD) ROE by Quarter and Year
Discovering the peaks and valleys of Affimed N.V. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 3.59%
Maximum Annual ROE = -0.81%
Minimum Annual Increase = -103.10%
Minimum Annual ROE = -183.26%
| Year | ROE | Change |
|---|---|---|
| 2023 | -183.26% | 225.84% |
| 2022 | -56.24% | 32.93% |
| 2021 | -42.31% | -26.36% |
| 2020 | -57.46% | -31.35% |
| 2019 | -83.70% | 72.45% |
| 2018 | -48.54% | -49.29% |
| 2017 | -95.71% | 15.12% |
| 2016 | -83.14% | 176.34% |
| 2015 | -30.08% | 3.59% |
| 2014 | -0.81% | -103.10% |
Affimed N.V. (AFMD) Average ROE
How has AFMD ROE performed in the past?
The current ROE of Affimed N.V. (AFMD) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-93.94%
5-year avg
-84.60%
10-year avg
-68.13%
Affimed N.V. (AFMD) ROE vs. Peers
How is AFMD’s ROE compared to its peers?
Affimed N.V.’s ROE is greater than TCR2 Therapeutics Inc. (-71.90%), greater than Pieris Pharmaceuticals, Inc. (-76.24%), less than ADC Therapeutics SA (131.30%), less than Agenus Inc. (131.89%), greater than X4 Pharmaceuticals, Inc. (-32.51%), greater than Terns Pharmaceuticals, Inc. (-32.76%), greater than Day One Biopharmaceuticals, Inc. (-22.40%), greater than PDS Biotechnology Corporation (-139.57%), greater than Inozyme Pharma, Inc. (-88.42%), greater than Leap Therapeutics, Inc. (-116.24%), greater than Adaptimmune Therapeutics plc (-74.84%), greater than Corvus Pharmaceuticals, Inc. (-167.55%), less than Aptose Biosciences Inc. (1.03%), less than eFFECTOR Therapeutics, Inc. (2.18%), greater than Elevation Oncology, Inc. (-59.73%), greater than Mereo BioPharma Group plc (-69.11%), greater than Hepion Pharmaceuticals, Inc. (-505.74%),
| Company | ROE | Market cap |
|---|---|---|
| -71.90% | $58.11M | |
| -76.24% | $17.96M | |
| 131.30% | $192.41M | |
| 131.89% | $63.81M | |
| -32.51% | $98.42M | |
| -32.76% | $503.69M | |
| -22.40% | $1.28B | |
| -139.57% | $62.47M | |
| -88.42% | $193.36M | |
| -116.24% | $110.74M | |
| -74.84% | $150.46M | |
| -167.55% | $292.37M | |
| 1.03% | $14.81M | |
| 2.18% | $941.00 | |
| -59.73% | $33.90M | |
| -69.11% | $524.55M | |
| -505.74% | $3.48M |
Build a custom stock screener for Affimed N.V. (AFMD) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Affimed N.V. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Affimed N.V. (AFMD) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Affimed N.V. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Affimed N.V.'s ROE?
How is the ROE calculated for Affimed N.V. (AFMD)?
What is the highest ROE for Affimed N.V. (AFMD)?
What is the 3-year average ROE for Affimed N.V. (AFMD)?
What is the 5-year average ROE for Affimed N.V. (AFMD)?
How does the current ROE for Affimed N.V. (AFMD) compare to its historical average?